Blurbs

Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), TG Therapeutics (TGTX) and Amneal Pharmaceuticals (AMRX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Delcath Systems (DCTHResearch Report), TG Therapeutics (TGTXResearch Report) and Amneal Pharmaceuticals (AMRXResearch Report) with bullish sentiments.

Delcath Systems (DCTH)

In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Delcath Systems, with a price target of $20.00. The company’s shares closed last Monday at $4.29, close to its 52-week low of $3.49.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 10.0% and a 37.6% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

Currently, the analyst consensus on Delcath Systems is a Strong Buy with an average price target of $18.00, implying a 321.5% upside from current levels. In a report issued on July 26, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $17.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TG Therapeutics (TGTX)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics today and set a price target of $17.00. The company’s shares closed last Monday at $7.00, close to its 52-week low of $3.48.

According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.9% and a 28.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TG Therapeutics with a $13.67 average price target, implying an 111.0% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $19.00 price target.

Amneal Pharmaceuticals (AMRX)

Goldman Sachs analyst Nathan Rich maintained a Buy rating on Amneal Pharmaceuticals today and set a price target of $4.00. The company’s shares closed last Monday at $3.17, close to its 52-week low of $2.90.

According to TipRanks.com, Rich is a 3-star analyst with an average return of 6.0% and a 56.9% success rate. Rich covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Bright Health Group, and Teva Pharmaceutical.

Currently, the analyst consensus on Amneal Pharmaceuticals is a Moderate Buy with an average price target of $4.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DCTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos